NCT03753087View on ClinicalTrials.gov

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

December 16, 2021

Study Completion Date

January 10, 2022

Conditions
Heart Failure, DiastolicDiabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

10 mg tablet

OTHER

Standard care

Standard care with no SGLT-2 inhibitors

Trial Locations (1)

121552

National Medical Research Center for Cardiology, Moscow

All Listed Sponsors
collaborator

Ministry of Health, Russian Federation

OTHER_GOV

lead

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

OTHER_GOV

NCT03753087 - Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter